Role of E6-AP in the Development of Prostate Cancer
E6-AP 在前列腺癌发展中的作用
基本信息
- 批准号:6778265
- 负责人:
- 金额:$ 6.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-30 至 2004-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (Provided by the applicant)
Androgens are important regulators of cell growth and prostate gland
development. Androgens exert their biological effects on target tissues through
an intracellular receptor protein named androgen receptor (AR). Recent evidence
suggests that transcriptional regulation by AR require a diverse group of
proteins termed coactivators. Coactivators portray a growing class of proteins
that interact with receptors in a hormone dependent manner and are required for
maximal gene activation by the receptors. It is the general belief that
coactivators enhance receptor function by acting as a bridge between the
DNA-bound receptor and basal transcription factors of the preinitiation complex
and also by providing histone acetyl transferase activity, HAT, which disrupts
the local repressive chromatin structure and contributes to increase
transcriptional activity. Recently, our laboratory has cloned, E6-associated
protein (E6-AP), as a coactivator of steroid receptors including that of AR.
E6-AP possesses ubiquitin-protein ligase activity, instead of HAT activity. Our
preliminary observation suggests that E6-AP act as a coactivator of AR and is
overexpressed both in mouse and human prostate tumors. The initial data from
E6-AP knockout mice also suggest that E6-AP play a major role in the normal
development of prostate gland. The prostate glands of the E6-AP knockout mice
are smaller and weigh less compare to that of wild-type normal littermates.
Furthermore, p53 levels are elevated in E6-AP knockout prostate glands.
Additionally, the AR expression is down in E6-AP knockout prostate. Based on
these initial findings, we hypothesize that E6-AP, an important modulator of
prostate gland, androgen receptor-mediated signal transduction pathway and cell
cycle control, is functionally significant in the development of normal
prostate gland and prostate cancer. In order to understand the exact role of
E6-AP in the development of normal prostate gland and in the development of
prostate tumors, we propose the following three specific aims: A) Development
and analysis of animal models for the overexpression of wild type E6-AP, C833S
mutant E6-AP (an E3 ubiquitin-protein ligase defective mutant) and loss of
E6-AP (E6-AP knockout) in the prostate gland, B), Design and development of
stable in vitro models for the overexpression of wild-type and C833S mutant
E6-AP proteins in the prostate cancer cell lines, and C) Expression analyses of
endogenous E6-AP, p53 and AR in prostate tumor biopsy samples.
描述(由申请人提供)
雄激素是细胞生长和前列腺的重要调节因子
发展雄激素通过以下途径对靶组织发挥其生物学作用:
一种名为雄激素受体(AR)的细胞内受体蛋白。最近的证据
表明AR的转录调控需要一组不同的
蛋白质称为coactivators。辅激活因子描绘了一类不断增长的蛋白质
以激素依赖的方式与受体相互作用,
最大程度地激活基因。人们普遍认为,
辅活化剂通过充当受体与受体之间的桥梁来增强受体功能。
前起始复合体的DNA结合受体和基础转录因子
还通过提供组蛋白乙酰转移酶活性,HAT,
局部抑制性染色质结构,并有助于增加
转录活性最近,我们的实验室克隆了E6相关的
蛋白(E6-AP),作为类固醇受体(包括AR受体)的共激活剂。
E6-AP具有泛素-蛋白连接酶活性,而不是HAT活性。我们
初步观察表明,E6-AP作为AR的共激活因子,
在小鼠和人前列腺肿瘤中均过表达。最初的数据来自
E6-AP基因敲除小鼠也表明E6-AP在正常的免疫反应中起主要作用。
前列腺的发育E6-AP基因敲除小鼠的前列腺
与野生型正常同窝仔相比更小且重量更轻。
此外,p53水平在E6-AP敲除的前列腺中升高。
此外,AR表达在E6-AP敲除前列腺中下降。基于
根据这些初步发现,我们假设E6-AP(一种重要的调节剂)
前列腺,雄激素受体介导的信号转导通路和细胞
周期控制,在正常发育中具有重要的功能意义,
前列腺和前列腺癌。为了理解
E6-AP在正常前列腺发育和前列腺增生中的作用
前列腺肿瘤,我们提出以下三个具体目标:
和野生型E6-AP、C833 S过表达的动物模型的分析
突变体E6-AP(E3泛素-蛋白连接酶缺陷突变体)和缺失
前列腺中的E6-AP(E6-AP敲除),B),
野生型和C833 S突变体过表达的稳定体外模型
前列腺癌细胞系中E6-AP蛋白的表达分析,和
内源性E6-AP、p53和AR。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zafar Nawaz其他文献
Zafar Nawaz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zafar Nawaz', 18)}}的其他基金
Roles of Novel Protein Complexes in Estrogen and Progesterone Receptor Signaling
新型蛋白质复合物在雌激素和孕激素受体信号传导中的作用
- 批准号:
8012326 - 财政年份:2010
- 资助金额:
$ 6.44万 - 项目类别:
Roles of Novel Protein Complexes in Estrogen and Progesterone Receptor Signaling
新型蛋白质复合物在雌激素和孕激素受体信号传导中的作用
- 批准号:
8213746 - 财政年份:2009
- 资助金额:
$ 6.44万 - 项目类别:
Roles of Novel Protein Complexes in Estrogen and Progesterone Receptor Signaling
新型蛋白质复合物在雌激素和孕激素受体信号传导中的作用
- 批准号:
8022886 - 财政年份:2009
- 资助金额:
$ 6.44万 - 项目类别:
Roles of Novel Protein Complexes in Estrogen and Progesterone Receptor Signaling
新型蛋白质复合物在雌激素和孕激素受体信号传导中的作用
- 批准号:
7752537 - 财政年份:2009
- 资助金额:
$ 6.44万 - 项目类别:
Roles of Novel Protein Complexes in Estrogen and Progesterone Receptor Signaling
新型蛋白质复合物在雌激素和孕激素受体信号传导中的作用
- 批准号:
7583457 - 财政年份:2009
- 资助金额:
$ 6.44万 - 项目类别:
COBRE: CREIGHTON UNIVERISTY:ADMINISTRATIVE CORE
COBRE:克雷顿大学:行政核心
- 批准号:
7171288 - 财政年份:2005
- 资助金额:
$ 6.44万 - 项目类别:
Role of E6-AP in the Development of Prostate Cancer
E6-AP 在前列腺癌发展中的作用
- 批准号:
6524667 - 财政年份:2001
- 资助金额:
$ 6.44万 - 项目类别:
Role of E6-AP in the Development of Prostate Cancer
E6-AP 在前列腺癌发展中的作用
- 批准号:
6645332 - 财政年份:2001
- 资助金额:
$ 6.44万 - 项目类别:
Role of E6-AP in the Development of Prostate Cancer
E6-AP 在前列腺癌发展中的作用
- 批准号:
7019806 - 财政年份:2001
- 资助金额:
$ 6.44万 - 项目类别:
Role of E6-AP in the Development of Prostate Cancer
E6-AP 在前列腺癌发展中的作用
- 批准号:
6442101 - 财政年份:2001
- 资助金额:
$ 6.44万 - 项目类别:
相似国自然基金
RKTG对ERK信号通路的调控和肿瘤生成的影响
- 批准号:30830037
- 批准年份:2008
- 资助金额:190.0 万元
- 项目类别:重点项目
相似海外基金
Prevention of Radiation-Induced Carcinogenesis by Senolytics
通过 Senolytics 预防辐射诱发的致癌作用
- 批准号:
23H03539 - 财政年份:2023
- 资助金额:
$ 6.44万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidation of Prostaglandin D Receptor-mediated Carcinogenesis Mechanism of Colitic Cancer
前列腺素D受体介导的结肠癌致癌机制的阐明
- 批准号:
23K08219 - 财政年份:2023
- 资助金额:
$ 6.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of carcinogenesis and symptoms associated with alcohol consumption
致癌的分子机制和饮酒相关症状
- 批准号:
23K05734 - 财政年份:2023
- 资助金额:
$ 6.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Chromatin-binding deubiquitinase MYSM1 as a putative drug target for cMYC-driven B cell lymphoma
染色质结合去泛素酶 MYSM1 作为 cMYC 驱动的 B 细胞淋巴瘤的推定药物靶点
- 批准号:
478278 - 财政年份:2023
- 资助金额:
$ 6.44万 - 项目类别:
Operating Grants
The mechanism of oral carcinogenesis by FAT1 gene mutation
FAT1基因突变导致口腔癌的机制
- 批准号:
23K15977 - 财政年份:2023
- 资助金额:
$ 6.44万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EGF Receptor Endocytosis: Mechanisms and Role in Signaling
EGF 受体内吞作用:机制及其在信号传导中的作用
- 批准号:
10552100 - 财政年份:2023
- 资助金额:
$ 6.44万 - 项目类别:
Mechanism of stringent translation initiation: a probe for its biological relevance
严格翻译起始机制:对其生物学相关性的探索
- 批准号:
10660217 - 财政年份:2023
- 资助金额:
$ 6.44万 - 项目类别:
Cytoprotective pathways in esophageal squamous epithelia
食管鳞状上皮的细胞保护途径
- 批准号:
10660394 - 财政年份:2023
- 资助金额:
$ 6.44万 - 项目类别:
NIH resubmission Deyu Li - Etheno adductome and repair pathways
NIH 重新提交 Deyu Li - 乙烯加合组和修复途径
- 批准号:
10659931 - 财政年份:2023
- 资助金额:
$ 6.44万 - 项目类别:
Project 2: Ex Vivo Modeling and Analysis of Gastric Precancerous Lesions
项目2:胃癌前病变的离体建模与分析
- 批准号:
10715763 - 财政年份:2023
- 资助金额:
$ 6.44万 - 项目类别:














{{item.name}}会员




